Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

Monopar Therapeutics Inc. (NASDAQ:MNPR) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Based on an average daily trading volume, of 66,900 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.3% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. HC Wainwright lifted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd. Piper Sandler started coverage on shares of Monopar Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $72.00 target price for the company.

Monopar Therapeutics Trading Up 0.9 %

Monopar Therapeutics stock traded up $0.26 during mid-day trading on Friday, hitting $29.75. The company had a trading volume of 20,431 shares, compared to its average volume of 361,716. Monopar Therapeutics has a 12 month low of $1.72 and a 12 month high of $54.30. The company has a market capitalization of $181.53 million, a PE ratio of -15.10 and a beta of 1.18. The stock’s 50 day moving average price is $35.77 and its two-hundred day moving average price is $21.41.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors have recently modified their holdings of MNPR. Janus Henderson Group PLC purchased a new position in shares of Monopar Therapeutics during the fourth quarter valued at approximately $23,435,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $13,182,000. RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics in the 4th quarter worth $11,247,000. Point72 Asset Management L.P. bought a new position in Monopar Therapeutics in the 4th quarter worth $3,694,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Monopar Therapeutics in the fourth quarter worth about $2,861,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.